Introduction
Guidelines for the appropriate and rational prescribing of antibacterial agents are being produced increasingly frequently. While antibiotic-prescribing policies for use locally in a particular hospital have existed for many years, newer guidelines are more comprehensive, in that they are more detailed and are not intended just for local use. They include not only recommendations concerning which antibacterials to prescribe, but also appropriate doses, duration of therapy and broader aspects of management, including laboratory investigations. [1] [2] [3] Current guidelines for the management of urinary tract infections (UTIs) are summarized elsewhere in this supplement. 4 With the increasing promulgation of guidelines, it is instructive to compare expert opinion on disease management with the actual usage of antimicrobials in practice. This report summarizes the results of an interactive session involving delegates at an international symposium on UTIs.
Materials and methods
Ninety-two symposium delegates, including microbiologists, infectious disease specialists and clinicians with an interest in therapy of UTIs, participated. This was an international group, 34 (37%) of the delegates coming from Nordic countries (Denmark, Norway, Sweden or Finland), 19 (21%) from the UK or Eire, 13 (14%) from Germany, Austria or Holland, 10 (11%) from Canada, eight (9%) from France, Switzerland or Belgium, three (3%) from Italy, Spain, Portugal or Greece and five (5%) from other countries.
Questions were posed by a moderator and the delegates used a key-pad to select an answer to each question. The overall response to each question was analysed and presented to the participants for information and discussion. The answers, which represented the delegates' perceived use of antibacterials, were compared with market data on actual use as provided by International Medical Statistics (IMS), Pinner, UK.
Results

Frequency of acute uncomplicated lower UTI
Before discussing the specific treatment of acute uncomplicated lower UTI, delegates were asked whether the number of prescriptions for this condition per annum per million inhabitants in western Europe and Canada was c.10 000, c.100 000 or c.250 000 prescriptions. In fact, in 1999, there were 46 million prescriptions per annum for acute uncomplicated lower UTI in western Europe and Canada, corresponding to a mean of 110 000 prescriptions per million inhabitants per annum. The delegates showed a good awareness of this: 14 (15%) of the delegates thought there were c.10 000 prescriptions/year, 59 (64%) thought there were c.100 000/year and 19 (21%) thought there were c.250 000 prescriptions/year. 
Antibiotic treatment for acute uncomplicated lower UTI
Delegates were asked to estimate the proportion of patients in their country with acute uncomplicated lower UTI treated with fluoroquinolones. The options provided were 0-10%, 11-20%, 21-30%, 31-40%, 41-50% or 51-71%. There was a broad range of estimates concerning fluoroquinolone usage in acute uncomplicated UTI. Forty-two (46%) of the delegates estimated that fluoroquinolones were used in р10% of patients with acute uncomplicated lower UTIs. Seventeen (18%) estimated their usage in 11-20%, 13 (14%) in 21-30%, 13 (14%) in 31-40% and seven (8%) in Ͼ50% of patients with acute uncomplicated lower UTIs.
The actual usage of antibiotics, expressed as a percentage of the total number of prescriptions for acute uncomplicated lower UTI, is shown in Table I . Fluoroquinolones (and other quinolones) are very widely used in the treatment of acute uncomplicated lower UTI. They are particularly heavily prescribed in Italy, Spain, Portugal, France, Switzerland and Belgium. There is less, but still considerable, use in Greece, Germany, Austria, The Netherlands and Canada. In the UK and Finland, use of these agents is lower.
Delegates were asked to state which of the following was the most frequently used antibiotic in western Europe and Canada for the treatment of acute uncomplicated UTI: trimethoprim, co-trimoxazole, pivmecillinam, nitrofurantoin, norfloxacin or ciprofloxacin. Delegates believed that co-trimoxazole and trimethoprim were the most popular treatments in Europe and Canada (Table II) . This was not the case in 1998/9 (Table II) . While there was considerable use of these agents, the quinolones, particularly norfloxacin and ciprofloxacin, were the most popular antibacterial agents in the treatment of acute uncomplicated lower UTI in 1999.
Pivmecillinam usage in Nordic countries
Pivmecillinam is a widely used treatment for acute uncomplicated lower UTI in Nordic countries. Participants were asked to estimate whether 5-10%, 11-20%, 21-25%, 26-30% or Ͼ30% of patients with acute uncomplicated UTI were treated with pivmecillinam in Scandinavia (Norway, Denmark and Sweden). Sixty-two delegates responded to this question; eight delegates (13%) estimated that 5-10% of patients with lower UTIs would be prescribed pivmecillinam, 23 (37%) chose the option 11-20%, 11 (18%) chose 21-25%, eight (13%) chose 26-30% and 12 (19%) chose Ͼ30% . Thus the delegates' estimates of pivmecillinam usage in Scandinavia varied widely, between 5-10% of patients and Ͼ30% of patients. The actual usage of pivmecillinam is shown in the Figure. In Scandinavia, between 15% and 30% of patients with acute uncomplicated UTI are treated with pivmecillinam.
Length of treatment for acute uncomplicated lower UTI
Delegates were asked to choose whether the current average length of treatment with co-trimoxazole, ciprofloxacin and fosfomycin trometamol for UTI was 1-3 days, 5-7 -spectrum penicillin  3  6  8  7  6  5  5  2  8  7  12  1  6  Cephalosporin  4  6  3  24  4  2  1  3  10  0  19  6  4  Fosfomycin  18  8  2  1  16  5  10  2  8  0  0  2  0  Nitrofurantoin  2  1  6  2  7  2  12  9  2  27  6  18  21  Pivmecillinam  0  0  1 
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days, 8-10 days or 11-14 days. As expected, delegates believed that short (р3 days) courses of a fluoroquinolone, such as ciprofloxacin, would be used (Table III) . Results for fosfomycin, for which single-dose treatment is advocated, were similar (Table III) .
Attitudes to the use of fluoroquinolones in acute uncomplicated lower UTI
After expressing their views concerning appropriate antibacterial therapy in uncomplicated UTI and observing data on the agents actually used, delegates were asked whether they felt that the current usage of fluoroquinolones in acute uncomplicated lower UTI was 'good' or 'bad' from a societal perspective, in terms of spread of resistance and impact on the environment. Seventy-seven (84%) of the delegates considered the current usage of fluoroquinolones to be 'bad' and 10 (11%) felt it was 'good'. Five delegates (5%) did not express an opinion.
First-line empirical treatment for acute uncomplicated lower UTI
At the end of the session, delegates were asked again to select, from the same choices as previously, the agent they would recommend as first-line empirical treatment for acute uncomplicated lower UTI. Thirty-two delegates (35%) chose trimethoprim, 27 (29%) pivmecillinam, 11 (12%) nitrofurantoin, 10 (11%) co-trimoxazole, two (2%) fluoroquinolones, two (2%) cephalosporins and eight (9%) 'others'.
Discussion
There was a preponderance of delegates from the Nordic countries, so the responses may show a bias towards the attitudes of Scandinavian microbiologists and infectious disease specialists. The agents recommended by symposium delegates as first-line empirical therapy for acute uncomplicated lower UTI were trimethoprim, pivmecillinam, co-trimoxazole, nitrofurantoin, fluoroquinolones and cephalosporins. The inclusion of pivmecillinam in this
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Pivmecillinam usage for uncomplicated UTI in Norway (---), Denmark (---) and Sweden (---). Actual fluoroquinolone use was much greater than most delegates expected. There was a general concern amongst participants about the amount of fluoroquinolone usage for uncomplicated UTI. Nearly 90% of the microbiologists and infectious disease clinicans in the survey felt that the level of current usage was inappropriate from a societal perspective. Although there was general agreement that these are effective for treating UTI, it was a general view that these agents were inappropriate first-line treatments, because of the risk of increased resistance, and that they should be reserved for complicated and refractory UTI and pyelonephritis.
The general trend towards a shorter duration of therapy for acute uncomplicated lower UTI 5 was endorsed by this survey of expert opinion.
The results of the survey were somewhat thoughtprovoking to participants, particularly regarding what many felt was excessive use of fluoroquinolones. This was apparent when delegates were asked again at the end of the session to recommend first-line empirical treatment for acute uncomplicated UTI. On the second occasion, there was an increase in the recommendation of pivmecillinam as a first-line treatment. The number of delegates who recommended fluoroquinolones for empirical use in UTI decreased from 10% to 2% after the delegates had seen data on the actual usage of these agents. This attitude is in general agreement with that of Piddock, 6 who recommended limited use of fluoroquinolones for first-line therapy in order to prevent the spread of resistance in pathogenic bacteria. 
